SOLIGENIX, INC. (SNGX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
25/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseSNGX / S&P -66.10% / 15.20% |
LoseSNGX / S&P SNGX unavailable / 15.00% |
LoseSNGX / S&P -77.90% / 50.40% |
| 2026-Q10/3 |
LoseSNGX / S&P -11.94% / -4.33% |
LoseSNGX / S&P SNGX unavailable / 11.30% |
LoseSNGX / S&P -63.81% / 27.70% |
| 2025-Q41/3 |
WinSNGX / S&P 15.52% / 2.65% |
LoseSNGX / S&P SNGX unavailable / 9.00% |
LoseSNGX / S&P -64.01% / 13.40% |
| 2025-Q30/3 |
LoseSNGX / S&P -11.45% / 8.12% |
LoseSNGX / S&P SNGX unavailable / 4.61% |
LoseSNGX / S&P -53.88% / 13.45% |
| 2025-Q20/3 |
LoseSNGX / S&P -39.07% / 10.94% |
LoseSNGX / S&P SNGX unavailable / 4.83% |
LoseSNGX / S&P -60.49% / 10.63% |
| 2025-Q10/3 |
LoseSNGX / S&P -20.37% / -4.27% |
LoseSNGX / S&P SNGX unavailable / 4.98% |
LoseSNGX / S&P -63.92% / 10.57% |
| 2024-Q40/3 |
LoseSNGX / S&P -31.99% / 2.41% |
LoseSNGX / S&P SNGX unavailable / 5.25% |
LoseSNGX / S&P -32.45% / 6.15% |
| 2024-Q31/3 |
WinSNGX / S&P 53.88% / 5.89% |
LoseSNGX / S&P SNGX unavailable / 5.89% |
LoseSNGX / S&P -2.31% / 6.11% |
| 2024-Q21/3 |
LoseSNGX / S&P -73.13% / 4.28% |
LoseSNGX / S&P -50.35% / 5.38% |
WinSNGX / S&P 47.18% / 5.12% |
| 2024-Q11/3 |
LoseSNGX / S&P -21.05% / 10.56% |
LoseSNGX / S&P -31.32% / 5.71% |
WinSNGX / S&P 218.90% / 5.59% |
| 2023-Q42/3 |
WinSNGX / S&P 35.71% / 11.69% |
LoseSNGX / S&P -11.55% / 6.81% |
WinSNGX / S&P 88.98% / 7.78% |
| 2023-Q31/3 |
LoseSNGX / S&P -20.00% / -3.27% |
LoseSNGX / S&P -30.07% / 7.52% |
WinSNGX / S&P -2.50% / -5.03% |
| 2023-Q21/3 |
LoseSNGX / S&P -64.47% / 8.74% |
LoseSNGX / S&P -28.52% / 9.50% |
WinSNGX / S&P -7.94% / -8.57% |
| 2023-Q10/3 |
LoseSNGX / S&P -70.81% / 7.50% |
LoseSNGX / S&P -26.23% / 10.77% |
LoseSNGX / S&P -40.65% / -15.69% |
| 2022-Q41/3 |
LoseSNGX / S&P 2.27% / 7.56% |
LoseSNGX / S&P -22.56% / 11.88% |
WinSNGX / S&P 2.56% / -17.99% |
| 2022-Q31/3 |
LoseSNGX / S&P -26.67% / -4.88% |
WinSNGX / S&P 90.78% / 13.47% |
LoseSNGX / S&P SNGX unavailable / -1.41% |
| 2022-Q21/3 |
LoseSNGX / S&P -17.81% / -16.10% |
WinSNGX / S&P 33.88% / 13.71% |
LoseSNGX / S&P SNGX unavailable / 11.04% |
| 2022-Q12/3 |
WinSNGX / S&P 10.61% / -4.60% |
WinSNGX / S&P 23.36% / 15.97% |
LoseSNGX / S&P SNGX unavailable / 42.23% |
| 2021-Q40/3 |
LoseSNGX / S&P -37.74% / 11.03% |
LoseSNGX / S&P -36.53% / 15.00% |
LoseSNGX / S&P SNGX unavailable / 96.40% |
| 2021-Q30/3 |
LoseSNGX / S&P -4.50% / 0.58% |
LoseSNGX / S&P -67.46% / 10.77% |
LoseSNGX / S&P SNGX unavailable / 69.42% |
| 2021-Q20/3 |
LoseSNGX / S&P -27.45% / 8.55% |
LoseSNGX / S&P -60.76% / 6.58% |
LoseSNGX / S&P SNGX unavailable / 51.81% |
| 2021-Q11/3 |
WinSNGX / S&P 19.53% / 6.17% |
LoseSNGX / S&P -67.30% / -1.06% |
LoseSNGX / S&P SNGX unavailable / 7.39% |
| 2020-Q40/3 |
LoseSNGX / S&P -28.49% / 12.15% |
LoseSNGX / S&P -39.96% / -3.72% |
LoseSNGX / S&P SNGX unavailable / -33.42% |
| 2020-Q30/3 |
LoseSNGX / S&P -15.17% / 8.93% |
LoseSNGX / S&P -34.98% / -2.04% |
LoseSNGX / S&P SNGX unavailable / -27.10% |
| 2020-Q21/3 |
WinSNGX / S&P 25.60% / 20.54% |
LoseSNGX / S&P -24.66% / -0.46% |
LoseSNGX / S&P SNGX unavailable / -27.11% |
| 2020-Q11/3 |
WinSNGX / S&P 15.86% / -19.60% |
LoseSNGX / S&P -10.62% / 3.47% |
LoseSNGX / S&P SNGX unavailable / -14.75% |
| 2019-Q41/3 |
WinSNGX / S&P 52.63% / 9.07% |
LoseSNGX / S&P -18.91% / 5.36% |
LoseSNGX / S&P SNGX unavailable / 2.99% |
| 2019-Q31/3 |
WinSNGX / S&P 33.80% / 1.70% |
LoseSNGX / S&P -19.75% / 5.02% |
LoseSNGX / S&P SNGX unavailable / 0.21% |
| 2019-Q20/3 |
LoseSNGX / S&P -22.83% / 4.30% |
LoseSNGX / S&P -22.99% / 6.64% |
LoseSNGX / S&P SNGX unavailable / 8.65% |
| 2019-Q10/3 |
LoseSNGX / S&P 6.98% / 13.65% |
LoseSNGX / S&P -8.77% / 8.12% |
LoseSNGX / S&P SNGX unavailable / 14.29% |
| 2018-Q40/3 |
LoseSNGX / S&P -54.26% / -13.52% |
LoseSNGX / S&P -16.50% / 9.05% |
LoseSNGX / S&P SNGX unavailable / 18.23% |
| 2018-Q31/3 |
WinSNGX / S&P 93.81% / 7.71% |
LoseSNGX / S&P -21.68% / 10.21% |
LoseSNGX / S&P -20.19% / 19.06% |
| 2018-Q20/3 |
LoseSNGX / S&P -50.26% / 3.43% |
LoseSNGX / S&P -34.49% / 9.03% |
LoseSNGX / S&P -34.56% / 14.46% |
| 2018-Q10/3 |
LoseSNGX / S&P -12.16% / -0.76% |
LoseSNGX / S&P -54.14% / 7.68% |
LoseSNGX / S&P -1.75% / 12.46% |
| 2017-Q40/3 |
LoseSNGX / S&P -0.45% / 6.64% |
LoseSNGX / S&P -54.55% / 7.03% |
LoseSNGX / S&P -17.02% / 13.82% |
| 2017-Q31/3 |
WinSNGX / S&P 8.78% / 4.48% |
LoseSNGX / S&P -53.80% / 5.68% |
LoseSNGX / S&P -48.26% / 17.57% |
| 2017-Q20/3 |
LoseSNGX / S&P -24.07% / 3.09% |
LoseSNGX / S&P -44.80% / 4.83% |
LoseSNGX / S&P -30.96% / 17.74% |
| 2017-Q11/3 |
WinSNGX / S&P 20.00% / 6.07% |
LoseSNGX / S&P -13.55% / 3.67% |
LoseSNGX / S&P -40.93% / 13.32% |
| 2016-Q41/3 |
LoseSNGX / S&P -70.78% / 3.82% |
WinSNGX / S&P 19.16% / 2.09% |
LoseSNGX / S&P -7.84% / 7.05% |
| 2016-Q33/3 |
WinSNGX / S&P 16.67% / 3.85% |
WinSNGX / S&P 51.81% / 0.20% |
WinSNGX / S&P 154.43% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | SNGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -87.74% | 20.78% |
| Annualized return | -87.74% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | SNGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.85% | 83.14% |
| Annualized return | -72.78% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | SNGX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.98% | 319.30% |
| Annualized return | -56.41% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |